DNA

Cmbio: A New Brand Unifying Leaders in Microbiome and Metabolomics Science

COPENHAGEN, Denmark, Nov. 19, 2024 /PRNewswire/ -- Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics…

1 year ago

Cloudforce’s Largest Donation to Create Tech Opportunities for Local Youth in Maryland

NATIONAL HARBOR, Md., Nov. 19, 2024 /PRNewswire/ -- Celebrating its 14th year, Maryland-based cloud and AI consultancy Cloudforce continues to…

1 year ago

New Partnership: Bioz Helps DNA Polymerase Technology to Boost Research Visibility Through Interactive Citation Badges

PALO ALTO, CA / ACCESSWIRE / November 19, 2024 / Bioz, Inc., a driving force in AI-enhanced citation tracking, is…

1 year ago

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens…

1 year ago

Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test

Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic…

1 year ago

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the…

1 year ago

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy…

1 year ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…

1 year ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…

1 year ago